These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34247513)

  • 1. Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.
    Trontzas IP; Rapti VE; Syrigos NK; Kounadis G; Perlepe N; Kotteas EA; Bamias G
    Immunotherapy; 2021 Sep; 13(13):1085-1092. PubMed ID: 34247513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
    Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
    J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.
    Läubli H; Hench J; Stanczak M; Heijnen I; Papachristofilou A; Frank S; Zippelius A; Stenner-Liewen F
    J Immunother Cancer; 2017; 5():46. PubMed ID: 28642817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
    Wills B; Brahmer JR; Naidoo J
    Curr Treat Options Oncol; 2018 Aug; 19(9):46. PubMed ID: 30101402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
    Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
    J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
    O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
    Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.